|
|||||
|
|
Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: Optimization of the aniline |
|
| Authors: | Richard Ducray Clifford D. JonesFrederic H. Jung Iain SimpsonJon Curwen Martin Pass |
| Affiliation: | a AstraZeneca, Oncology Innovative Medicines, Centre de recherches, Z.I. la Pompelle, 51689 Reims Cedex 2, France b AstraZeneca, Oncology Innovative Medicines, Alderley Park, Macclesfield, SK10 4TG, UK |
| Abstract: | Following the discovery of imidazopyridine 1 as a potent IGF-1R tyrosine kinase inhibitor, the aniline part has been modified with the aim to optimize the properties of this series. The structure-activity relationships against IGF-1R kinase activity as well as inhibition of the hERG ion channel are discussed. |
| Keywords: | IGF1-R Insulin-like growth factor-1 receptor Kinase inhibitor |
| 本文献已被 ScienceDirect 等数据库收录！ | |